Letters

WHO perspective on preventing avoidable harm from medicines

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7554.1393-b (Published 08 June 2006) Cite this as: BMJ 2006;332:1393
  1. Mary R Couper (couperm@who.int), medical officer,
  2. Shanthi N Pal, technical officer,
  3. Lembit Rägo, coordinator,
  4. Jacqueline Sawyer, technical officer
  1. Department of Medicines Policy and Standards, World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland
  2. Department of Medicines Policy and Standards, World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland

    EDITOR—The BMJ news item on adverse drug reactions is important.1 The estimated annual expenditure of $870m towards issues related to such effects would be hard on any economy; such figures could seriously cripple countries with lesser resources.

    The cost factor should then be at least one of the reasons for all developing countries to promote pharmacovigilance. Started in 1968, the World Health …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe